Released Sep 2, 2026, after the close
10-Q filed Sep 2, 2026, 64 days after period end · 0001193125-26-380228
On September 2, 2026, Attovia Therapeutics, Inc. (the “Company”) issued a press release reporting its financial results for the second quarter ended June 30, 2026.
The release| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Revenue | $450.00K | $0.00 |
| Net Income | -$20.69M | -$14.44M |
| EPS Diluted | -$4.88 | -$3.71 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Attovia Therapeutics, Inc. · CIK 2058707 · Engraved from SEC EDGAR
ATTO-1310 showed rapid, deep itch relief in chronic pruritus and high-itch atopic dermatitis, and Phase 2 studies are planned for the first half of 2027.¶2¶3¶4
Attovia completed an upsized IPO with aggregate gross proceeds of approximately $332.4 million and said its current cash, cash equivalents and marketable securities will fund operations into 2030.¶5¶6
For the quarter ended June 30, 2026, collaboration revenue was $0.5 million, research and development expenses were $18.9 million, general and administrative expenses were $3.3 million, and net loss was $20.7 million.¶7¶8¶9¶10